← All trials
NCT00074412
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- Sep 1, 2011
- Completion date
- Nov 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 2026
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of NatalStudy chair
- Johns Hopkins UniversityStudy chair
- Stanford UniversityStudy chair
- Harvard UniversityStudy chair
- National Institute on Drug Abuse (NIDA)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.